Results 131 to 140 of about 177,018 (304)
CD19 is a surface antigen on B cells that regulates B cell activation and proliferation, participating in B cell signaling. It is expressed in all B cell lineage tumor diseases, making CD19 a significant marker for detecting B cell tumor diseases and an ...
Liya Shen +8 more
doaj +1 more source
Long non-coding RNA profiling of human lymphoid progenitor cells reveals transcriptional divergence of B cell and T cell lineages. [PDF]
To elucidate the transcriptional 'landscape' that regulates human lymphoid commitment during postnatal life, we used RNA sequencing to assemble the long non-coding transcriptome across human bone marrow and thymic progenitor cells spanning the earliest ...
Casero, David +8 more
core
Sono‐Mechanogenetics: Linking Ultrasound Physics With Cellular Mechanobiology
Sono‐mechanogenetics links ultrasound physics with cellular mechanotransduction to enable noninvasive control of engineered biological systems. Acoustic forces generate distinct deformation modes that activate intracellular signaling pathways, which can be coupled to synthetic gene circuits to regulate diverse cellular functions, including gene ...
Yunjia Qu +4 more
wiley +1 more source
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs +4 more
wiley +1 more source
TAX2‐NPs capture extracellular TSP‐1 in the injured liver and promote its macrophage‐mediated autophagic degradation. This process blocks TSP‐1/CD47 signaling, restores VEGFR2‐AKT activity, preserves endothelial function, and mitigates hepatic ischemia‐reperfusion injury.
Haorui Wang +12 more
wiley +1 more source
BackgroundCD19 combined with CD22 or CD20 therapy is a promising immunotherapy approach for the treatment of hematological malignancies. Dual-targeted CD19/CD22 CAR T and CD19/CD22 CAR T-cell therapy are currently being evaluated in clinical trials, and ...
Xiaoshuang Yuan +13 more
doaj +1 more source
Genetic Code Expanded T Cell for Controllable Immunotherapy
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang +4 more
wiley +1 more source

